Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

A Arcari, A Chiappella, M Spina, L Zanlari… - Leukemia & …, 2016 - Taylor & Francis
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose
chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and …
被引用次数：40 相关文章

[引用][C] Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

A Arcari, A Chiappella, M Spina, L Zanlari… - LEUKEMIA & …, 2016 - iris.unical.it
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell
lymphoma patients: an Italian retrospective multicenter study. IRIS IRIS Home Sfoglia …

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

A Arcari, A Chiappella, M Spina, L Zanlari… - LEUKEMIA & …, 2016 - iris.unimore.it
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose
chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and …

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

A Arcari, A Chiappella, M Spina… - Leukemia & …, 2016 - search.ebscohost.com
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose
chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and …

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

A Arcari, A Chiappella, M Spina, L Zanlari… - Leukemia & …, 2015 - europepmc.org
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose
chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and …

[引用][C] Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

A Arcari, A Chiappella, M Spina, L Zanlari… - LEUKEMIA & …, 2016 - ricerca.uniba.it
Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell
lymphoma patients: an Italian retrospective multicenter study IRIS IRIS Home Sfoglia …

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

A Arcari, A Chiappella, M Spina… - Leukemia & …, 2016 - pubmed.ncbi.nlm.nih.gov
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose
chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and …

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

A Arcari, A Chiappella, M Spina, L Zanlari… - LEUKEMIA & …, 2016 - research.unipd.it
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose
chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and …